Normalization of mass spectra acquired by mass spectrometric imaging
View Patent ↗Mass spectra acquired by imaging mass spectrometry (IMS), in particular MALDI imaging of tissue sections, are each normalized by one of: the p-norm of the mass spectrum transformed by applying an exclusion list, the p-norm of the mass spectrum transformed by square rooting the intensity values, the median of the mass spectrum, and the median absolute deviation of the noise level of the mass spectrum.
1. A method for determining the spatial distribution of a biomarker, drug or metabolite of a drug in a tissue with different types of cells, the method comprising:
providing a section of the tissue;
acquiring a set of mass spectra at a plurality of spatially-separated pixel locations of the tissue section;
identifying mass ranges in the mass spectra that correspond to tissue compounds that are inhomogeneously distributed within the tissue section and produce mass signals with high intensity or large areas under the peak in confined regions of the tissue section;
determining a p-norm of each of the mass spectra as transformed by the application of an intensity value exclusion list that suppresses the mass signals in the identified mass ranges;
normalizing each mass spectrum using the p-norm determined for that mass spectrum; and
deriving a mass image of the biomarker, drug or drug metabolite from the normalized mass spectra and determining the spatial distribution of the biomarker, drug or drug metabolite in the tissue.
2. The method according to claim 1 , wherein the mass image is a first mass image and wherein the method further comprises:
(a) normalizing each mass spectrum by computing a p-norm of that mass spectrum without transformation of the mass spectrum by application of an exclusion list;
(b) deriving a second mass image of the biomarker, drug or drug metabolite from the mass spectra normalized in step (a); and
(c) comparing the first and second mass images and determining the spatial distribution from the second mass image when the first and second mass images are substantially similar, otherwise determining the spatial distribution from the first mass image.
3. The method according to claim 1 , wherein the mass spectra of the mass spectrometric imaging data set are acquired by MALDI imaging.
4. The method according to claim 1 , wherein the p-norm is the total ion count.
5. The method according to claim 1 , wherein the identified mass ranges of the exclusion list are such that the distribution of noise or the mass images of abundant and homogeneously distributed mass signals do not comprise holes in the mass spectra.
6. The method according to claim 1 , wherein the mass signals of the exclusion list are predetermined according to tissue type.
7. The method according to claim 6 , wherein the tissue comprises pancreatic tissue and the identified mass ranges of the exclusion list comprise a mass signal that corresponds to insulin and the confined regions of the tissue section comprise islets of Langerhans.
8. The method according to claim 6 , wherein the tissue comprises brain tissue and the identified mass ranges of the exclusion list comprise mass signals of abundant beta-amyloid peptides.
9. The method according to claim 1 , wherein the determined mass image of the biomarker, drug or drug metabolite is displayed.
10. A method for determining the spatial distribution of the kind or state of a tissue with different types of cells, the method comprising:
providing a section of the tissue;
acquiring a set of mass spectra at a plurality of spatially-separated pixel locations of the tissue section;
identifying mass ranges in the mass spectra that correspond to tissue compounds that are inhomogeneously distributed within the tissue section and produce mass signals with high intensity or large areas under the peak in confined regions of the tissue section;
determining a p-norm of each of the mass spectra as transformed by the application of an intensity value exclusion list that suppresses the mass signals in the identified mass ranges;
normalizing each mass spectrum using the p-norm determined for that mass spectrum; and
deriving a mass image of the of the kind or state of the tissue by combining at least two different mass signals of the normalized mass spectra and determining the spatial distribution of the kind or state of the tissue from the mass image.